

CLASSIFICATION: DUAL GIP/GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~ 5 DAYS
DOSAGE: 2.5–5 MG WEEKLY
ACNE: NOT REPORTED
WATER RETENTION: NOT REPORTED
HIGH BLOOD PRESSURE (HBP): POSSIBLE
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: PEPTIDE HUBS
LABORATORY TESTED: VIEW LAB RESULTS
Peptide Hubs Tirzep 5 mg delivers high-purity Tirzepatide for advanced weight management and metabolic enhancement. Each 2 mL vial contains 5 mg of lab-tested Tirzepatide, formulated for consistent research quality and maximum potency.
Tirzep contains Tirzepatide, a dual GIP and GLP-1 receptor agonist. It supports weight loss, improves insulin sensitivity, and helps regulate appetite and blood glucose levels. Tirzepatide has gained attention as a promising option for obesity and type 2 diabetes management [Clinical Study].
Research protocols typically start with low doses (e.g., 2.5–5 mg weekly) and titrate upward depending on tolerance. Subcutaneous injection is the common administration method. Professional medical supervision is strongly recommended when researching Tirzepatide.
For enhanced metabolic benefits, consider stacking with Retatrutide by Peptide Hubs. Explore more advanced research peptides in the Peptide Hubs USA category.
Peptide Hubs is dedicated to supplying lab-tested peptides manufactured with strict quality control, offering researchers access to premium-grade compounds for professional study purposes.
Tirzep is used in research for promoting weight loss, improving insulin sensitivity, regulating blood glucose levels, and supporting overall metabolic health through dual GIP and GLP-1 receptor activation.
Typical research protocols start at 2.5–5 mg weekly administered subcutaneously, with gradual dose escalation depending on tolerance and study goals.
Tirzepatide has shown a favorable safety profile in clinical trials, but side effects like gastrointestinal discomfort and mild hypertension have been reported. Professional supervision is advised.
You can purchase lab-tested Tirzep 5 mg from our Peptide Hubs USA section, featuring premium-quality research peptides.
Please log in to write TIRZEP 5 MG review.
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (20 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: STEALTH LABS USA
LABORATORY TESTED: VIEW LAB RESULTS
SHIPPED WITHOUT LABEL!
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: KALPA PHARMACEUTICALS
CLASSIFICATION: RECOMBINANT HUMAN GROWTH HORMONE (rHGH)
ACTIVE SUBSTANCE: SOMATROPIN
FORM: 1 PRE-FILLED PEN x 36 IU (12 MG)
ACTIVE HALF-LIFE: ~3.5 HOURS (SUBQ)
DOSAGE: 1–4 IU/DAY FOR ANTI-AGING; 4–8 IU/DAY FOR FAT LOSS OR PERFORMANCE
WATER RETENTION: POSSIBLE (DOSE DEPENDENT)
HEPATOTOXICITY: NONE
AROMATIZATION: NO
MANUFACTURER: PFIZER
CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: HUMAN CHORIONIC GONADOTROPIN
FORM: 1 ML AMP x 5000 IU
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: MODERATE
HIGH BLOOD PRESSURE (HBP): UNLIKELY
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY ELEVATES ESTROGEN
MANUFACTURER: SUN PHARMA
CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: PRE-MIXED HUMAN CHORIONIC GONADOTROPIN
FORM: 1 VIAL x 10000 IU (READY-TO-INJECT)
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: LOW to MODERATE
HIGH BLOOD PRESSURE (HBP): RARE
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY INCREASES ESTROGEN
MANUFACTURER: BHARAT SERUMS AND VACCINES
CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: PRE-MIXED HUMAN CHORIONIC GONADOTROPIN
FORM: 1 VIAL x 5000 IU (READY-TO-INJECT)
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: LOW to MODERATE
HIGH BLOOD PRESSURE (HBP): RARE
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY INCREASES ESTROGEN
MANUFACTURER: BHARAT SERUMS AND VACCINES
CLASSIFICATION: NATURAL HORMONE
ACTIVE SUBSTANCE: HUMAN CHORIONIC GONADOTROPIN
FORM: 1 AMP [2 ML PER AMP] x 10000 IU
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3 TIMES/WEEK (ON-CYCLE OR PCT)
ACNE: POSSIBLE
WATER RETENTION: LOW
HIGH BLOOD PRESSURE (HBP): RARE
HEPATOTOXICITY: NO
AROMATIZATION: INDIRECTLY ELEVATES ESTROGEN
MANUFACTURER: SUN PHARMACEUTICALS